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CASE REPORT

Diabetic Ketoacidosis Precipitated by Pembrolizumab: A
Case Report on the Challenges of Long-Term Management
Sarosh Khan1, Sunam Sujanani, MD2
1
2

College of Osteopathic Medicine, University of New England, Biddeford, ME
Northern Light Eastern Maine Medical Center, Internal Medicine, Bangor, ME

Introduction:

Pembrolizumab (Keytruda®) is a potent and selective humanized monoclonal immunoglobulin
antibody that blocks programmed cell death-1 on T cells, augmenting the antitumor immune response.
Pembrolizumab is an approved adjuvant therapy for treating metastatic melanoma.

Clinical Findings: A 75-year-old man with metastatic melanoma developed diabetic ketoacidosis before receiving a sixth
cycle of pembrolizumab.
Clinical Course:

He received intravenous insulin, fluids, and electrolyte repletion per the diabetic ketoacidosis protocol.
He presented again to the emergency room with profound hyperglycemia 1 week after discharge.
Following a second round of treatment, his home insulin regimen was titrated for better glycemic control,
and pembrolizumab was discontinued.

Conclusions:

As cases of diabetes associated with immune checkpoint inhibitor therapy are increasingly reported,
challenges may include adequately managing diabetes long-term, preventing diabetic ketoacidosis,
and discontinuing pembrolizumab due to immune-related adverse effects.
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A

When he presented to the cancer care center to
receive the sixth cycle of pembrolizumab, his
blood sugar was 784 mg/dL (Figure 1), and he
complained of excessive thirst, urination, fatigue,
and weakness developing in the last week. His
physical exam showed that he was in significant
distress with tachycardia, poor skin turgor, and
epigastric tenderness. Based on further evaluation,
he showed hyperglycemia, hyponatremia, and
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75-year-old man was diagnosed with stage
IIIB malignant melanoma of the left upper arm.
Following a local excision and a left axillary
sentinel lymph node dissection, the man was given
adjuvant therapy with 400 mg intravenous (IV)
pembrolizumab every 6 weeks starting in June 2020.
His past medical history included surveillance for
low-grade prostate cancer, essential hypertension,
and pre-diabetes.
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Figure 1. Blood Glucose Level Before Each Cycle of
Pembrolizumab

metabolic acidosis (Table 1). He also met the
criteria for diabetic ketoacidosis (DKA). He started
a DKA protocol with administration of IV insulin at
0.14 units/kg/hour based on his weight of 90.7 kg,
IV fluids, and electrolyte repletion.
1
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Table 1. Laboratory Values During Each Emergency
Room Admission and Hospitalization
ER
ER
visit 1 visit 2 Reference
Sodium, mEq/L

127

128

136-145

Potassium, mEq/L

5.0

4.9

3.5-5.0

Chloride, mEq/L

88

92

95-105

Bicarbonate,
mEq/L

17

24

22-28

Anion gap, mEq/L

22

12

3-10

BUN, mg/dL

51

31

7-18

Creatinine, mg/dL

1.57

1.34

0.6-1.2

Average estimated
42
eGFR

51

75 (for ages
70+)
<140 mg/dL
(non-fasting)

Glucose

784

562

pH blood

7.18

7.35

7.35-7.45

Urine glucose

>500

>500

None

Urine ketones

Present

Trace None

pH urine

5.0

5.0

4.6-8.0

Abbreviations: BUN, blood urea nitrogen; eGFR,
estimated glomerular filtration rate; ER, emergency
room.

After the anion gap normalized, on the second
day of hospitalization, he was given insulin on a
sliding scale. His acute kidney injury secondary to
DKA resolved with administration of IV fluids. He
was discharged on day 4 of hospitalization with a
new diagnosis of diabetes mellitus secondary to
pembrolizumab, and he was advised to continue
taking 15 units of insulin glargine at night and 500
mg twice daily of metformin. He was asked to follow
up with his primary care physician, given a new
referral for endocrinology, and taught to use and
monitor his blood glucose levels.
However, 7 days after discharge, our patient called
his primary care physician’s office, reporting a blood
glucose level of 525 mg/dL. He presented to the
emergency room again with fatigue and reported
a 20-pound weight loss in the last 3 months (Table
2). He received IV fluids, 10 units of IV insulin, and
electrolyte repletion in the emergency room. The
next day, he was discharged with the following
insulin regimen: 18 units of insulin glargine at
bedtime and 4 units of insulin lispro pre-meal.
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Table 2. Characteristics
Hospitalization

During

Labs
Weight, kg
90.7
C-peptide, ng/mL
<0.1 (L)
Lipase level, IU/L
90 (H)
Insulin antibody
Negative
Glutamic acid decar- Negative
boxylase antibody
IA-2 autoantibody
Negative
TSH, μU/mL
1.64
Cortisol, μg/dL*
10.4
ACTH, pg/mL*
25.2

Second

Reference
0.5-2.7
15-55
Negative
Negative
Negative
0.5-5.0
10-20
7.2-63.3

Abbreviations: ACTH, adrenocorticotropic hormone; IA2, islet tyrosine phosphatase 2; TSH, thyroid-stimulating
hormone.
*Measured between 6 AM and 8 AM.

Two days after the second hospitalization,
our patient presented to his oncologist, where
pembrolizumab adjuvant therapy was discontinued
and a new PET/CT (positron emission tomography/
computed tomography) scan was scheduled. The
next day, he presented for his first appointment
with an endocrinologist. Based on his recent blood
glucose levels, his insulin regimen was titrated to
increase insulin glargine to 24 units every morning
and increase insulin aspart to 10 units with breakfast
and lunch and 6 units with dinner.

DISCUSSION
Pembrolizumab (Keytruda®) is a potent and
selective humanized monoclonal immunoglobulin
antibody that blocks programmed death receptor-1
on T cells, thereby augmenting the antitumor
immune response.1,2 Clinical trials showed that
pembrolizumab significantly increased progressionfree survival in non-small-cell lung cancer, overall
survival in refractory melanoma, and overall
response rates to treatments for advanced
melanoma.3-5 In December 2015, the Food and Drug
Administration approved pembrolizumab as adjuvant
therapy for treating unresectable or metastatic
melanoma.6,7 Studies estimated that 0.2% of people
undergoing treatment with pembrolizumab develop
diabetes.8,9 A number of case reports highlighted
DKA as the first clinical presentation of autoimmune
diabetes among patients undergoing treatment
2
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with pembrolizumab.10-24 Of note, one case of DKA
induced by autoimmune diabetes occurred within
3 weeks after a single dose of pembrolizumab.25
In a review of 71 cases of diabetes induced by
an immune checkpoint inhibitor (ICI), the mean
age of onset was 61.7 years, 55% of cases were
men, and melanoma was the most frequent type
of cancer.26 Furthermore, in all these case reports,
permanent exogenous insulin was the mainstay
of treatment for long-term management, and
significant hyperglycemia occurred in a short time.26
In a separate review of 90 case reports of diabetes
mellitus caused by ICI therapy, 71% of cases
presented with DKA as the first sign of diabetes.27
The mechanism by which ICIs cause autoimmune
diabetes is not fully understood. One possible
mechanism may be the destruction of pancreatic
beta islet cells by host T cells, which are no longer
inhibited due to the immunotherapy agents.28
Specifically, immune-related adverse events may
be due to reduced self-tolerance mediated by T
cells, B cells, autoantibodies, and cytokines. In
addition, emerging studies are investigating the
role of epigenetics, environmental factors, immune
status, and intestinal microbiota in the propensity to
develop immune-related adverse effects associated
with ICI therapy.
In the case of our patient, his ultimate insulin
regimen exceeded his insulin requirement while
he was hospitalized. This finding supports past
evidence that patients with ICI-induced diabetes
have varying levels of insulin sensitivity.29 In addition,
our patient’s C-peptide level was undetectable and
islet autoantibodies were negative. In their review,
deFilette et al. reported that 53% of patients with ICIinduced diabetes had positive islet autoantibodies.27
This positivity may pose a challenge to clinicians
who cannot predict the development of insulindeficient diabetes by monitoring islet antibodies,
which has been used in cases of type 1 diabetes.30
Clinical challenges remain in the long-term
management of new onset diabetes secondary
to pembrolizumab. These challenges include
uncovering its clear etiology, adequate glycemic
control to prevent DKA, and lack of a clear protocol
for discontinuing ICI therapy.
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